Mirum Pharmaceuticals, Inc. (MIRM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$324.9M
Cash & Equivalents
$228.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$5,935M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (3 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
MARALIXIBAT CHLORIDE
LIVMARLI |
APPROVED | Acid Sphingomyelinase Deficiency, Adrenoleukodystrophy, Alagille Syndrome, Alagille Syndrome (ALGS), Bile Acid Synthesis Defect, Bile Acid Synthesis Disorders, Biliary Atresia, Cerebrotendinous Xanthomatosis, Ceroid Lipofuscinosis, Neuronal, 2, Cholestasis, Cholestasis, Intrahepatic, Cholestatic Liver Disease, Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC), Chronic Hepatitis D, Chronic Hepatitis D Infection, CTX, Fabry Disease, Fragile X Syndrome, Gaucher Disease, GM1 Gangliosidosis, Healthy Volunteers, Inborn Errors of Bile Acid Synthesis, Infantile Refsum's Disease, Intrahepatic Cholestasis of Pregnancy, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C, Non-alcoholic Steatohepatitis, PBC, Peroxisomal Disorders, PFIC - Progressive Familial Intrahepatic Cholestasis, Primary Biliary Cholangitis, Primary Biliary Cirrhosis, |
|
CHENODIOL
CTEXLI |
APPROVED | — |
|
CHOLIC ACID
CHOLBAM |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.